Epidemiologic considerations to assess altered DNA methylation from environmental exposures in cancer

Annals of the New York Academy of Sciences

Volumn 983, Issue , 2003, Pages 181-196

  Moore, Lee E ^a   Huang, Wen Yi ^a   Chung, Joyce ^b   Hayes, Richard B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DNA methylation; Environmental carcinogenesis; Epidemiology; Epigenetics

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC; BIOLOGICAL MARKER; CADMIUM; CHROMIC ACID; HISTONE; METAL DERIVATIVE; NICKEL; SELENIUM; TRACE ELEMENT; XENOBIOTIC AGENT;

ACETYLATION; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONFERENCE PAPER; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; GENETIC DAMAGE; GENETIC EPIDEMIOLOGY; GENETIC SUSCEPTIBILITY; HUMAN; NONHUMAN; RISK ASSESSMENT; TECHNIQUE;

EID: 0037354509     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb05973.x     Document Type: Conference Paper

References (117)

1. BAYLIN, S.B., J.G. HERMAN, J.R. GRAFF, et al. 1998. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72: 141-196.
2. BESTOR, T.H. & B. TYCKO. 1996. Creation of genomic methylation patterns. Nat. Genet. 12: 363-367.
3. COSTELLO, J.F. & C. PLASS. 2001. Methylation matters. J. Med. Genet. 38: 285-303.
4. YODER, J.A., C.P. WALSH & T.H. BESTOR. 1997. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 13: 335-340.
5. BIRD, A.P. & A.P. WOLFFE. 1999. Methylation-induced repression - belts, braces, and chromatin. Cell 99: 451-454.
6. SHEN, L., N. AHUJA, Y. SHEN, et al. 2002. DNA methylation and environmental exposures in human hepatocellular carcinoma. J. Natl. Cancer Inst. 94: 755-761.
7. KANAI, Y., S. USHIJIMA, Y. KONDO, et al. 2001. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int. J. Cancer 91: 205-212.
8. RASHID, A., L. SHEN, J.S. MORRIS, et al. 2001. CpG island methylation in colorectal adenomas. Am. J. Pathol. 159: 1129-1135.
9. CHAN, A.O., J.P. ISSA, J.S. MORRIS, et al. 2002. Concordant CpG island methylation in hyperplastic polyposis. Am. J. Pathol. 160: 529-536.
10. TOYOTA, M., N. AHUJA, M. OHE-TOYOTA, et al. 1999. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 96: 8681-8686.
11. ROBERTSON, K.D. & P.A. JONES. 1997. Dynamic interrelationships between DNA replication, methylation, and repair. Am. J. Hum. Genet. 61: 1220-1224.
12. GONZALGO, M.L. & P.A. JONES. 1997. Mutagenic and epigenetic effects of DNA methylation. Mutat. Res. 386: 107-118.
13. JONES, P.A. & S.B. BAYLIN. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415-428.
14. ROTHMAN, N., W.F. STEWART & P.A. SCHULTE. 1995. Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories. Cancer Epidemiol. Biomarkers Prev. 4: 301-311.
15. SLATTERY, M.L., J.D. POTTER, W. SAMOWITZ, et al. 1999. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol. Biomarkers Prev. 8: 513-518.
16. DE LA VEGA, M.J., F. SANTOLARIA, E. GONZALEZ-REIMERS, et al. 2001. High prevalence of hyperhomocysteinemia in chronic alcoholism: the importance of the thermolabile form of the enzyme methylenetetrahydrofolate reductase (MTHFR). Alcohol 25: 59-67.
17. WAGNER, C. 1985. Folate-binding proteins. Nutr. Rev. 43: 293-299.
18. HERBERT, V. 1986. The role of vitamin B12 and folate in carcinogenesis. Adv. Exp. Med. Biol. 206: 293-311.
19. KIM, Y.I., I.P. POGRIBNY, A.G. BASNAKIAN, et al. 1997. Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am. J. Clin. Nutr. 65: 46-52.
20. JACOB, R.A., D.M. GRETZ, P.C. TAYLOR, et al. 1998. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in post-menopausal women. J. Nutr. 128: 1204-1212.
21. LASHNER, B.A. 1993. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J. Cancer Res. Clin. Oncol. 119: 549-554.
22. MEYER, F. & E. WHITE. 1993. Alcohol and nutrients in relation to colon cancer in middle-aged adults. Am. J. Epidemiol. 138: 225-236.
23. BIRD, C.L., M.E. SWENDSEID, J.S. WITTE, et al. 1995. Red cell and plasma folate, folate consumption, and the risk of colorectal adenomatous polyps. Cancer Epidemiol. Biomarkers Prev. 4: 709-714.
24. CRAVO, M.L., J.B. MASON, Y. DAYAL, et al. 1992. Folate deficiency enhances the development of colonic neoplasia in dimethylhydrazine-treated rats. Cancer Res. 52: 5002-5006.
25. KIM, Y.I., I.P. POGRIBNY, R.N. SALOMON, et al. 1996. Exon-specific DNA hypomethylation of the p53 gene of rat colon induced by dimethylhydrazine. Modulation by dietary folate. Am. J. Pathol. 149: 1129-1137.
26. CROTT, J.W., S.T. MASHIYAMA, B.N. AMES & M. FENECH. 2001. The effect of folic acid deficiency and MTHFR C677T polymorphism on chromosome damage in human lymphocytes in vitro. Cancer Epidemiol. Biomarkers Prev. 10: 1089-1096.
27. TITENKO-HOLLAND, N., R.A. JACOB, N. SHANG, et al. 1998. Micronuclei in lymphocytes and exfoliated buccal cells of postmenopausal women with dietary changes in folate. Mutat. Res. 417: 101-114.
28. AMES, B.N. 1998. Micronutrients prevent cancer and delay aging. Toxicol. Lett. 102-103: 5-18.
29. AMES, B.N. 2001. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat. Res. 475: 7-20.
30. NYCE, J. 1989. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res. 49: 5829-5836.
31. NYCE, J., S. LEONARD, D. CANUPP, et al. 1993. Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc. Natl. Acad. Sci. USA 90: 2960-2964.
32. NYCE, J.W. 1997. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat. Res. 386: 153-161.
33. WILSON, V.L. & P.A. JONES. 1983. DNA methylation decreases in aging but not in immortal cells. Science 220: 1055-1057.
34. HARTWIG, A. 1995. Current aspects in metal genotoxicity. Biometals 8: 3-11.
35. HARTWlG, A., R. SCHLEPEGRELL, H. DALLY & M. HARTMANN. 1996. Interaction of carcinogenic metal compounds with deoxyribonucleic acid repair processes. Ann. Clin. Lab. Sci. 26: 31-38.
36. COSTA, M., J.E. SUTHERLAND, W. PENG, et al. 2001. Molecular biology of nickel carcinogenesis. Mol. Cell Biochem. 222: 205-211.
37. LEE, Y.W., C.B. KLEIN, B. KARGACIN, et al. 1995. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol. Cell Biol. 15: 2547-2557.
38. KLEIN, C.B., K. CONWAY, X.W. WANG, et al. 1991. Senescence of nickel-transformed cells by an X chromosome: possible epigenetic control. Science 251: 796-799.
39. BRODAY, L., W. PENG, M.H. KUO, et al. 2000. Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res. 60: 238-241.
40. ZHAO, C.Q., M.R. YOUNG, B.A. DIWAN, et al. 1997. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. USA 94: 10907-10912.
41. SCHROEDER, M. & M.J. MASS. 1997. CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem Biophys. Res. Commun. 235: 403-406.
42. NATIONAL RESEARCH COUNCIL. 1999. Arsenic in drinking water. U.S.E.P.A., National Academy of Sciences. Washington, DC.
43. YAMANAKA, K., M. HOSHINO, M. OKAMOTO, et al. 1990. Induction of DNA damage by dimethylarsine, a metabolite of inorganic arsenics, is for the major part likely due to its peroxyl radical. Biochem. Biophys. Res. Commun. 168: 58-64.
44. LEE, T.C., N. TANAKA, P.W. LAMB, et al. 1988. Induction of gene amplification by arsenic. Science 241: 79-81.
45. MOORE, L.E., A.H. SMITH, C. ENG, et al. Arsenic-related chromosomal changes in bladder cancer. J. Natl. Cancer Inst. 94: 1688-1696.
46. LI, J.H. & T.G. ROSSMAN. 1989. Inhibition of DNA ligase activity by arsenite: a possible mechanism of its comutagenesis. Mol. Toxicol. 2: 1-9.
47. ANDREW, A.S., M.R. KARAGAS & A.H.J.W. SCHNED. 2002. Decreased expression of DNA repair genes ERCC1, XPF, and XPB, but not XPG or XPA among individuals exposed to arsenic in drinking water (abstr.). American Association for Cancer Research, 43.
48. WARNER, M.L., L.E. MOORE, M.T. SMITH, et al. 1994. Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol. Biomarkers Prev. 3: 583-590.
49. RAMIREZ, P., D.A. EASTMOND, J.P. LACLETTE & P. OSTROSKY-WEGMAN. 1997. Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Mutat. Res. 386: 291-298.
50. MOORE, L.E., M.L. WARNER, A.H. SMITH, et al. 1996. Use of the fluorescent micronucleus assay to detect the genotoxic effects of radiation and arsenic exposure in exfoliated human epithelial cells. Environ. Mol. Mutagen. 27: 176-184.
51. MOORE, L.E., A.H. SMITH, C. HOPENHAYN-RICH, et al. 1997. Micronuclei in exfoliated bladder cells among individuals chronically exposed to arsenic in drinking water. Cancer Epidemiol. Biomarkers Prev. 6: 31-36.
52. GONSEBATT, M.E., L. VEGA, A.M. SALAZAR, et al. 1997. Cytogenetic effects in human exposure to arsenic. Mutat. Res. 386: 219-228.
53. EASTMOND, D.A. & J.D. TUCKER. 1989. Identification of aneuploidy-inducing agents using cytokinesis-blocked human lymphocytes and an antikinetochore antibody. Environ. Mol. Mutagen. 13: 34-43.
54. ABERNATHY, C.O., Y.P. LIU, D. LONGFELLOW, et al. 1999. Arsenic: health effects, mechanisms of actions, and research issues. Environ. Health Perspect. 107: 593-597.
55. CAVIGELLI, M., W.W. LI, A. LIN, et al. 1996. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 15: 6269-6279.
56. BURLESON, F.G., P.P. SIMEONOVA, D.R. GERMOLEC & M.I. LUSTER. 1996. Dermatotoxic chemical stimulate of c-jun and c-fos transcription and AP-1 DNA binding in human keratinocytes. Res. Commun. Mol. Pathol. Pharmacol. 93: 131-148.
57. SHIMIZU, M., J.F. HOCHADEL, B.A. FULMER & M.P. WAALKES. 1998. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Toxicol. Sci. 45: 204-211.
58. CHEN, N.Y., W.Y. MA, C. HUANG, M. DING & Z. DONG. 2000. Activation of PKC is required for arsenite-induced signal transduction. J. Environ. Pathol. Toxicol. Oncol. 19: 297-305.
59. TROUBA, K.J., E.M. WAUSON & R.L. VORCE. 2000. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol. Appl. Pharmacol. 164: 161-170.
60. PORTER, A.C., G.R. FANGER & R.R. VAILLANCOURT. 1999. Signal transduction pathways regulated by arsenate and arsenite. Oncogene 18: 7794-7802.
61. ZAKHARYAN, R.A., A. SAMPAYO-REYES, S.M. HEALY, et al. 2001. Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol. 14: 1051-1057.
62. ZAKHARYAN, R.A. & H.V. APOSHIAN. 1999. Enzymatic reduction of arsenic compounds in mammalian systems: the rate-limiting enzyme of rabbit liver arsenic biotransformation is MMA(V) reductase. Chem. Res. Toxicol. 12: 1278-1283.
63. HOPENHAYN-RICH, C., M.L. BIGGS, A.H. SMITH, et al. 1996. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ. Health Perspect. 104: 620-628.
64. HOPENHAYN-RICH, C., M.L. BIGGS, D.A. KALMAN, et al. 1996. Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Environ. Health Perspect. 104: 1200-1207.
65. VAHTER, M. & G. CONCHA. 2001. Role of metabolism in arsenic toxicity. Pharmacol. Toxicol. 89: 1-5.
66. NATIONAL RESEARCH COUNCIL. 2001. Arsenic in Drinking Water, Update. U.S. E.P.A., National Academy of Sciences. Washington, DC.
67. BUCHET, J.P., R. LAUWERYS & H. ROELS. 1981. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int. Arch. Occup. Environ. Health 48: 71-79.
68. MARAFANTE, E., M. VAHTER & J. ENVALL. 1985. The role of the methylation in the detoxication of arsenate in the rabbit. Chem. Biol. Interact. 56: 225-238.
69. VAHTER, M., E. MARAFANTE & L. DENCKER. 1983. Metabolism of arsenobetaine in mice, rats and rabbits. Sci. Total Environ. 30: 197-211.
70. KITCHIN, K.T. 2001. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172: 249-261.
71. STYBLO, M., L.M. DEL RAZO, et al. 2000. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 74: 289-299.
72. MASS, M.J., A. TENNANT, B.C. ROOP, et al. 2001. Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol. 14: 355-361.
73. PETRICK, J.S., F. AYALA-FIERRO, W.R. CULLEN, et al. 2000. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163: 203-207.
74. DAVIS, C.D., E.O. UTHUS & J.W. FINLEY. 2000. Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J. Nutr. 130: 2903-2909.
75. YU, R.C., K.H. HSU, C.J. CHEN & J.R. FROINES. 2000. Arsenic methylation capacity and skin cancer. Cancer Epidemiol. Biomarkers Prev. 9: 1259-1262.
76. HSUEH, Y.M., H.Y. CHIOU, Y.L. HUANG, et al. 1997. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol. Biomarkers Prev. 6: 589-596.
77. VAHTER, M. & E. MARAFANTE. 1987. Effects of low dietary intake of methionine, choline or proteins on the biotransformation of arsenite in the rabbit. Toxicol. Lett. 37: 41-46.
78. HASSOUN, B.S., I.S. PALMER & C. DWIVEDI. 1995. Selenium detoxification by methylation. Res. Commun. Mol. Pathol. Pharmacol. 90: 133-142.
79. JIANG, C., W. JIANG, C. IP, et al. 1999. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol. Carcinog. 26: 213-225.
80. IP, C., D.J. LISK & H.E. GANTHER. 2000. Chemoprevention with triphenylselenonium chloride in selenium-deficient rats. Anticancer Res. 20: 4179-4182.
81. STYBLO, M. & D.J. THOMAS. 2001. Selenium modifies the metabolism and toxicity of arsenic in primary rat hepatocytes. Toxicol. Appl. Pharmacol. 172: 52-61.
82. COONEY, C.A. 2001. Dietary selenium and arsenic affect. DNA methylation J. Nutr. 131: 1871-1872.
83. HIROSE, T., K. KONDO, Y. TAKAHASHI, et al. 2002. Frequent microsatellite instability in lung cancer from chromate-exposed workers. Mol. Carcinog. 33: 172-180.
84. HUANG, C., Q. ZHANG, J. LI, et al. 2001. Involvement of Erks activation in cadmium-induced AP-1 transactivation in vitro and in vivo. Mol. Cell Biochem. 222: 141-147.
85. MAIER, A., T.P. DALTON & A. PUGA. 2000. Disruption of dioxin-inducible phase I and phase II gene expression patterns by cadmium, chromium, and arsenic. Mol. Carcinog. 28: 225-235.
86. KONDO, K., N. HINO, M. SASA, et al. 1997. Mutations of the p53 gene in human lung cancer from chromate-exposed workers. Biochem. Biophys. Res. Commun. 239: 95-100.
87. PEREIRA, M.A., P.M. KRAMER, P.B. CONRAN & L. TAO. 2001. Effect of chloroform on dichloroacetic acid and trichloroacetic acid-induced hypomethylation and expression of the c-myc gene and on their promotion of liver and kidney tumors in mice. Carcinogenesis 22: 1511-1519.
88. ISSA, J.P., S.B. BAYLIN & S.A. BELINSKY. 1996. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res. 56: 3655-3658.
89. MOORE, L.E., A.H. SMITH, M. BATES, et al. 2002. Bladder cancer in an arsenic endemic area and polymorphisms in folate metabolism and glutathione S-transferase (abstr.). American Association for Cancer Research, 43.
90. SKIBOLA, C.F., M.T. SMITH, E. KANE, et al. 1999. Polymorphisms in the methylenetet-rahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc. Natl. Acad. Sci. USA 96: 12810-12815.
91. MORRISON, K., C. PAPAPETROU, F.A. HOL, et al. 1998. Susceptibility to spina bifida; an association study of five candidate genes. Ann. Hum. Genet. 62 (Pt. 5): 379-396.
92. TSAI, M. Y., M. BIGNELL, F. YANG, et al. 2000. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis 149: 131-137.
93. TSAI, M.Y., B.G. WELGE, N.Q. HANSON, et al. 1999. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis 143: 163-170.
94. WILSON, A., D. LECLERC, D.S. ROSENBLATT & R.A. GRAVEL. 1999. Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism. Hum. Mol. Genet. 8: 2009-2016.
95. RAMSBOTTOM, D., J.M. SCOTT, A. MOLLOY, et al. 1997. Are common mutations of cystathionine beta-synthase involved in the aetiology of neural tube defects? Clin. Genet. 51: 39-42.
96. BROUWER, O.F., W. ONKENHOUT, P.M. EDELBROEK, et al. 1992. Increased neurotoxicity of arsenic in methylenetetrahydrofolate reductase deficiency. Clin. Neurol. Neurosurg. 94: 307-310.
97. LIANG, G., M.F. CHAN, Y. TOMIGAHARA, et al. 2002. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol. Cell Biol. 22: 480-491.
98. RHEE, I., K.E. BACHMAN, B.H. PARK, et al. 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556.
99. TRINH, B.N., T.I. LONG, A.E. NICKEL, et al. 2002. DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol. Cell Biol. 22: 2906-2917.
100. LI, E., T.H. BESTOR & R. JAENISCH. 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69: 915-926.
101. GILLILAND, F.D., H.J. HARMS, R.E. CROWELL, et al. 2002. Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum. Cancer Res. 62: 2248-2252.
102. LEE, W.H., R.A. MORTON, J.I. EPSTEIN, et al. 1994. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91: 11733-11737.
103. CAIRNS, P., M. ESTELLER, J.G. HERMAN, et al. 2001. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7: 2727-2730.
104. LEE, W.H., W.B. ISAACS, G.S. BOVA & W.G. NELSON. 1997. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol. Biomarkers Prev. 6: 443-450.
105. LIN, X., M. TASCILAR, W.H. LEE, et al. 2001. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 159: 1815-1826.
106. BROOKS, J.D., M. WEINSTEIN, X. LIN, et al. 1998. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev. 7: 531-536.
107. HANSEN, W.K. & M.R. KELLEY. 2000. Review of mammalian DNA repair and translational implications. J. Pharmacol. Exp. Ther. 295: 1-9.
108. INOUE, R., M. ABE, Y. NAKABEPPU, et al. 2000. Characterization of human polymorphic DNA repair methyltransferase. Pharmacogenetics 10: 59-66.
109. JUBB, A.M., S.M. BELL & P. QUIRKE. 2001. Methylation and colorectal cancer. J. Pathol. 195: 111-134.
110. CHANEY, S.G. & A. SANCAR. 1996. DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst. 88: 1346-1360.
111. OLIVER, F.J., J. MENISSIER-DE MURCIA & G. DE MURCIA. 1999. Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis, and disease. Am. J. Hum. Genet. 64: 1282-1288.
112. KREKLAU, E.L., M. LIMP-FOSTER, N. LIU, et al. 2001. A novel fluorometric oligonucleotide assay to measure O(6)-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing inethylpurine DNA glycosylase. Nucleic Acids Res. 29: 2558-2566.
113. ISSA, J.P. 2000. The epigenetics of colorectal cancer. Ann. N.Y. Acad. Sci. 910: 140-153.
114. ESTELLER, M. & J.G. HERMAN. 2002. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors. J. Pathol. 196: 1-7.
115. SIDRANSKY, D. 2002. Emerging molecular markers of cancer. Nat. Rev. Cancer 2: 210-219.
116. SUZUKI, H., E. GABRIELSON, W. CHEN, et al. 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31: 141-149.
117. COMMITTEE ON BIOLOGICAL MARKERS OF THE NATIONAL RESEARCH COUNCIL. 1987. Biological markers in environmental health research. Environ. Health Perspect. 74: 3-9.